Latest News on EXEL

Financial News Based On Company


Advertisement
Advertisement

Exelixis (EXEL) Investor Conference Run Keeps Fair Value Questions In Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-investor-conference-run-keeps-fair-value-quest
Exelixis (EXEL) is participating in several investor conferences in November, putting its oncology portfolio and capital allocation strategies under scrutiny from institutional investors. Despite recent short-term share price volatility, the company has seen significant gains year-to-date and over five years. Analysts at Simply Wall St currently view Exelixis as 9% overvalued, with a fair value of $61.57, while market multiples suggest it might be undervalued compared to peers, raising questions about the true risk/reward profile.

Morgan Stanley maintains Exelixis at Equal-Weight, lowers price target to $57 from $60

https://www.tradingview.com/news/tradingview:f972aa218d1f5:0-morgan-stanley-maintains-exelixis-at-equal-weight-lowers-price-target-to-57-from-60/
Morgan Stanley has reiterated its "Equal-Weight" rating for Exelixis (EXEL) but has reduced its price target from $60 to $57, representing a 5.0% decrease. This new target implies an 18.4% downside from the stock's closing price of $69.84 on November 12. Other recent analyst actions on Exelixis show price targets ranging from $58 to $78.

Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.

https://www.fool.com/investing/2026/11/13/exelixis-has-2-major-catalysts-coming-by-march-202/
Exelixis, a biotech company, is nearing a new growth phase driven by its next-generation cancer candidate, zanzalintinib. The company has two significant catalysts expected by March 2027: a U.S. FDA decision on zanzalintinib for metastatic colorectal cancer and phase 3 trial data for another indication. These events could significantly boost revenue if positive, though they also carry inherent risks for investors.

Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib

https://www.tradingview.com/news/marketbeat:cd7ebfbd4094b:0-exelixis-nears-fda-decision-key-kidney-cancer-data-for-zanzalintinib/
Exelixis is approaching a crucial period with an early March FDA decision expected for its cancer drug zanzalintinib in combination with atezolizumab for colorectal cancer. The company also anticipates top-line results in the first quarter of next year from a Phase 3 kidney cancer study (STELLAR-304) for zanzalintinib. Chief Strategy Officer Andrew Peters highlighted the company's transition towards a business with multiple drug franchises beyond its existing cabozantinib franchise, with zanzalintinib representing over $5 billion in potential opportunity across its seven pivotal studies.

Eight Farallon funds hold the shares behind a passive stake in Exelixis (EXEL).

https://www.stocktitan.net/sec-filings/EXEL/schedule-13g-exelixis-inc-passive-investment-disclosure-5-a34774c790c4.html
Farallon Capital Management, L.L.C. and its managing members have reported a 6% passive stake in Exelixis (EXEL) through a Schedule 13G filing. This beneficial ownership amounts to 14,694,910 shares, with shared voting and dispositive power held by eight specific Farallon Funds. The filing identifies Farallon Capital Management as the investment manager for these funds and lists various individuals associated with the firm as reporting persons.
Advertisement

A 12 million-share Exelixis (EXEL) stake falls below the 5% ownership threshold.

https://www.stocktitan.net/sec-filings/EXEL/schedule-13d-a-exelixis-inc-amended-major-shareholder-report-f4e1b6e28c88.html
Farallon Capital Management, L.L.C., along with several individual reporting persons, has reported that their shared beneficial ownership of Exelixis (EXEL) common shares has fallen to 4.9%, or 12,017,906 shares. This amendment to a Schedule 13D filing indicates that these parties ceased to be beneficial owners of more than 5% of EXEL's shares on November 6, 2026. The percentage is based on 244,010,895 shares outstanding as of October 19, 2026.

Exelixis stock: Q3 revenue rises as zanzalintinib advances

https://www.ad-hoc-news.de/boerse/news/corporate-news/exelixis-stock-q3-revenue-rises-as-zanzalintinib-advances/70472159
Exelixis reported strong third-quarter results, with revenue and GAAP net income increasing year-over-year, primarily driven by its cabozantinib franchise. The company maintained its full-year 2026 revenue guidance but lowered its effective tax-rate range. A key focus remains on zanzalintinib, with an FDA action date set for March 3, 2027, for its colorectal cancer application.

Handa Pharmaceuticals' First Three Quarters Profit Falls Over 70%; Originator Files New Patent Infringement Suit, Shares Hit Limit Down

https://finance.biggo.com/news/f629e5e4-6a20-4582-a46a-f9eff9d8b26f
Handa Pharmaceuticals reported a substantial decline in net profit and earnings per share for the first three quarters of 2026, primarily due to a high comparison base from last year's one-time licensing revenue and increased competition for its generic drug. Concurrently, Exelixis, the originator of HND-039 Omcazio, filed a new patent infringement lawsuit against Handa, causing the company's shares to hit a limit-down price. Handa stated it would actively respond to the litigation and continue its commercialization efforts for HND-039, which recently received final FDA approval.

Exelixis Inc stock hits all-time high at 73.49 USD

https://www.investing.com/news/company-news/exelixis-inc-stock-hits-alltime-high-at-7349-usd-93CH-5004887
Exelixis Inc (EXEL) stock reached an all-time high of $73.49, trading just 1% below its 52-week peak, reflecting strong investor confidence and a 79.12% surge over the past year. The biotechnology company reported robust third-quarter earnings, surpassing Wall Street expectations, with adjusted EPS of $0.94 and revenue of $658.69 million. Analysts maintain a positive outlook, with BMO Capital raising its price target to $60, signaling continued potential for success in the biotech industry.

Exelixis Inc stock hits all-time high at 73.49 USD By Investing.com

https://ca.investing.com/news/stock-market-news/exelixis-inc-stock-hits-alltime-high-at-7349-usd-93CH-4935500
Exelixis Inc (EXEL) stock reached an all-time high of $73.49, trading just 1% below its 52-week peak, reflecting a 79.12% surge over the past year. The company's strong performance is supported by a P/E ratio of 21.8 and a low PEG ratio of 0.49, suggesting an attractive valuation. Recent Q3 earnings surpassed expectations, with adjusted earnings of $0.94 per share and revenue of $658.69 million, leading BMO Capital to raise its price target to $60.
Advertisement

What Was Exelixis Telling You Before Its Stock Ran?

https://www.trefis.com/stock/exel/articles/621822/what-was-exelixis-telling-you-before-its-stock-ran/2026-11-01
Exelixis (EXEL) saw its stock return 76.0% between October 2025 and October 2026, significantly outperforming the S&P 500. This surge followed the FDA's acceptance of its experimental cancer drug, zanzalintinib, which the company had been highlighting to investors since February 2025. Despite public trial results showing positive outcomes, the stock's major run-up occurred later when the regulatory process advanced.

Exelixis, Inc. Stock 12‑Month Price Target Raised to $59.69, Implies 10% Downside

https://www.tradingview.com/news/tradingview:4b74f4d66aef9:0-exelixis-inc-stock-12-month-price-target-raised-to-58-29-implies-12-downside/
The average 12-month price target for Exelixis, Inc. stock has increased to $59.69 from $55.5, based on estimates from 13 analysts. This updated target suggests a potential 10% downside from the October 29 closing price. The consensus rating among 18 analysts has shifted to "Hold," with 5 Buys, 11 Holds, and 2 Sells.

Exelixis, Inc. Stock 12‑Month Price Target Raised to $59.21, Implies 11% Downside

https://www.tradingview.com/news/tradingview:4b74f4d66aef9:0-exelixis-inc-stock-12-month-price-target-raised-to-59-21-implies-11-downside/
Exelixis, Inc. (EXEL) has seen its average 12-month price target raised to $59.21 by 14 analysts, with forecasts ranging from $41 to $76 per share. This updated target suggests an 11% potential downside from the October 29 closing price. Despite this, the consensus rating from 19 covering analysts remains a "Buy," with 6 Buys, 11 Holds, and 2 Sells.

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.biospace.com/press-releases/exelixis-announces-third-quarter-2026-financial-results-and-provides-corporate-update
Exelixis reported strong third-quarter 2026 financial results, with total revenues of $658.7 million, driven by the cabozantinib franchise. The company is advancing its pipeline, particularly with zanzalintinib, which has ongoing pivotal trials and an FDA review for metastatic colorectal cancer with a PDUFA target action date of March 3, 2027. Exelixis also updated its full-year 2026 financial guidance and continued its stock repurchase program.

Exelixis, Inc. Stock 12‑Month Price Target Raised to $59.69, Implies 10% Downside

https://www.tradingview.com/news/tradingview:4b74f4d66aef9:0-exelixis-inc-stock-12-month-price-target-raised-to-55-93-implies-16-downside/
Exelixis, Inc.'s average 12-month price target has been raised from $55.5 to $59.69 by 13 analysts, with forecasts ranging from $41 to $76 per share. This updated target implies an approximately 10% potential downside based on the Oct. 29 closing price. The consensus rating for EXEL has shifted to "Hold" among 18 covering analysts, comprising 5 Buys, 11 Holds, and 2 Sells.
Advertisement

Exelixis (NASDAQ:EXEL) Q3 Earnings Beat, Revenue In Line as Guidance Holds

https://www.chartmill.com/news/EXEL/Chartmill-57285-Exelixis-NASDAQEXEL-Q3-Earnings-Beat-Revenue-In-Line-as-Guidance-Holds
Exelixis (NASDAQ:EXEL) reported strong third-quarter 2026 results, beating earnings estimates and meeting revenue expectations. The oncology company maintained its full-year revenue guidance, lowered its expected tax rate, and advanced its zanzalintinib pipeline. Despite revenue guidance being slightly below consensus, the market reacted positively due to the EPS beat and pipeline progress.

Exelixis, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:EXEL)

https://seekingalpha.com/article/4959747-exelixis-inc-2026-q3-results-earnings-call-presentation
Exelixis, Inc. published its slide deck in conjunction with its Q3 2026 earnings call. This presentation provides details on the company's financial results for the third quarter. The article was written by the Seeking Alpha transcripts team.

Exelixis: Q3 Earnings Snapshot

https://www.kens5.com/article/syndication/associatedpress/exelixis-q3-earnings-snapshot/616-3087e752-92db-4d0f-bcd9-581db4f9347c
Exelixis Inc. (EXEL) reported a strong third quarter, with profits reaching $218.1 million or 85 cents per share. Adjusted earnings of 94 cents per share surpassed analyst expectations of 89 cents. The drug developer also exceeded revenue forecasts, posting $658.7 million against an expected $653.1 million, and provided a full-year revenue outlook between $2.5 billion and $2.55 billion.

Exelixis stock hits all-time high at 65.62 USD

https://www.investing.com/news/company-news/exelixis-stock-hits-alltime-high-at-6562-usd-93CH-4979572
Exelixis Inc. stock has reached an all-time high of $65.62, marking a 65.53% increase over the past year due to strong performance and investor confidence in its cancer therapies. While InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value, its PEG ratio of 0.35 indicates attractive value when considering growth prospects. Recent developments include an FDA review extension for zanzalintinib and varying price target adjustments from Citizens and BMO Capital.

Exelixis Inc. Common Stock (EXEL) Financial Statements

https://pluang.com/en/asset/usstock/EXEL/11376/financial
This article provides key financial information and trading data for Exelixis Inc. Common Stock (EXEL). It highlights the company's market capitalization, trading volume, sector, and its 52-week high and low prices. The content also guides users on how to track, buy, and sell EXEL shares on the Pluang platform, an OJK-regulated investment super app.
Advertisement

Earnings Preview: Exelixis to Report Financial Results Post-market on October 29

https://www.moomoo.com/news/post/1002244481/earnings-preview-exelixis-to-report-financial-results-post-market-on
Exelixis (EXEL) is scheduled to announce its financial results post-market on October 29. Investors will be keen to see if the company can surpass revenue and earnings per share estimates, and hear management's outlook for the upcoming quarter.

Exelixis, Inc. Estimates – NASDAQ:EXEL

https://www.tradingview.com/symbols/NASDAQ-EXEL/financials-estimates/
The article provides a financial overview of Exelixis, Inc. (NASDAQ: EXEL) on TradingView, covering its actual financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. It highlights the ability to compare actual results with average, high, and low estimates, and visualize financial trends over time. The content explicitly states it is not investment advice and encourages users to conduct their own research.

Exelixis, Inc. Estimates – LSX:936718

https://www.tradingview.com/symbols/LSX-936718/financials-estimates/
This page provides financial actuals and analyst estimates for Exelixis, Inc. (LSX:936718) on the Lang & Schwarz Exchange, accessible via TradingView. Users can explore reported financial data and compare it against average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance

https://finviz.com/news/406053/exelixis-faces-a-test-of-its-trimmed-outlook-as-street-models-run-above-guidance
Exelixis is approaching its third-quarter earnings report with a discrepancy between its lowered 2026 revenue guidance and the Street's higher consensus estimates, prompting a critical evaluation of its outlook. The company had previously cut its full-year forecast due to a slower ramp-up for cabozantinib in neuroendocrine tumors, yet its stock has rallied since. The upcoming report will determine if the guidance cut was conservative or indicative of a softer growth period, with analysts expecting non-GAAP earnings of $0.89 a share on revenue of $653.1 million.

Exelixis Inc stock hits all-time high at 63.39 USD

https://www.investing.com/news/company-news/exelixis-inc-stock-hits-alltime-high-at-6339-usd-93CH-4960323
Exelixis Inc (EXEL) stock has reached an all-time high of $63.39, driven by an 81.5% total return over the past year. The biopharmaceutical company, now valued at $15.6 billion, shows attractive valuation metrics with a P/E ratio of 19.67 and a PEG ratio of 0.34, despite being considered overvalued by InvestingPro analysis. Recent developments include an FDA review extension for zanzalintinib and reiterated "Market Outperform" ratings from Citizens.
Advertisement

Citizens lifts target to USD 65 for Exelixis stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/citizens-lifts-target-to-usd-65-for-exelixis-stock/70377566
Citizens has increased its price target for Exelixis (EXEL) stock from USD 55.00 to USD 65.00, maintaining a Market Outperform rating. This revision follows Exelixis' Q2 2026 revenue of USD 628.69 million, an increase of 10.60% year-over-year, and positive presentations at ESMO 2026 regarding cabozantinib. The new target represents an 18.18% increase from the previous target and stands above the stock's current Nasdaq price.

Exelixis Inc stock hits all-time high at 63.39 USD By Investing.com

https://ca.investing.com/news/stock-market-news/exelixis-inc-stock-hits-alltime-high-at-6339-usd-93CH-4891085
Exelixis Inc. (EXEL) stock reached an all-time high of $63.39, marking an 81.5% total return over the past year and valuing the biopharmaceutical company at $15.6 billion. Despite an InvestingPro analysis suggesting the stock is overvalued, its P/E ratio of 19.67 and PEG ratio of 0.34 indicate an attractive valuation relative to growth. Recent developments include an FDA review extension for zanzalintinib, reaffirmed and raised price targets from Citizens, and new coverage from BMO Capital.

EXEL Maintained by Citizens -- Price Target Raised to $65.00

https://www.gurufocus.com/news/9129694/exel-maintained-by-citizens-price-target-raised-to-6500
Citizens has maintained a 'Market Outperform' rating for Exelixis (EXEL), increasing its price target to $65.00, suggesting confidence in the company's growth potential. Despite this positive outlook, GuruFocus indicates EXEL is 32.3% overvalued at its current price of $62.23, and insider selling has been observed. Investors are advised to consider the strong GF Score against the overvaluation and insider activity.

Citizens raises Exelixis stock price target to $65 on ESMO data

https://ca.investing.com/news/stock-market-news/citizens-raises-exelixis-stock-price-target-to-65-on-esmo-data-93CH-4887647
Citizens has increased its price target for Exelixis Inc. (NASDAQ:EXEL) shares to $65.00 from $55.00, maintaining a Market Outperform rating. This adjustment comes ahead of ESMO 2026, where several presentations on Exelixis's cabozantinib are expected, including Phase 1/2 data for advanced GEP-NETs and updates on other trials. Despite a strong stock performance and attractive PEG ratio, InvestingPro suggests the stock is currently overvalued based on its Fair Value.

Exelixis stock sits 1.83 percent below its 52-week high on October 16

https://www.ad-hoc-news.de/boerse/news/nebenwerte/exelixis-stock-sits-1-83-percent-below-its-52-week-high-on-october-16/70350606
Exelixis stock was 1.83 percent below its 52-week high on October 16, 2026, with a Nasdaq quote of USD 62.23. RBC Capital recently raised its target price for the stock from USD 45.00 to USD 51.00. The company issued revenue guidance of USD 2.50-2.55 billion for 2026, excluding potential zanzalintinib approval revenues.
Advertisement

Exelixis (NasdaqGS:EXEL) Stock Price

https://simplywall.st/stock/nasdaqgs/exel
Exelixis (NasdaqGS:EXEL) stock is currently trading at US$64.39, with a fair value estimate of US$54.87, indicating it is 17.4% overvalued according to the analyst consensus target. Analyst narratives discuss varying outlooks, from a bullish view expecting oncology pipeline growth to a bearish perspective highlighting regulatory and patent risks. The company, an oncology firm focusing on difficult-to-treat cancers, reported US$2.4 billion in revenue and US$860.6 million in earnings, with its next earnings report scheduled for October 29, 2026.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

https://www.biospace.com/press-releases/exelixis-to-release-third-quarter-2026-financial-results-on-thursday-october-29-2026
Exelixis, Inc. (Nasdaq: EXEL) announced it will release its third-quarter 2026 financial results on Thursday, October 29, 2026, after market close. Following the release, management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Interested parties can register via the provided link for conference call access or view the live webcast on the company’s website.

Exelixis to release Q3FY26 results on Oct 29, 2026

https://scanx.trade/stock-market-news/companies/exelixis-release-q3fy26-results-oct-29-2026/53649498
Exelixis, Inc. announced that it will release its third quarter 2026 financial results on Thursday, October 29, 2026, after the market close. The company will host a conference call and webcast at 5:00 pm ET / 2:00 pm PT to discuss the results and provide a general business update. Access to the event will be available via the company’s website, with a webcast replay archived for one year.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

https://investingnews.com/exelixis-to-release-third-quarter-2026-financial-results-on-thursday-october-29-2026/
Exelixis, Inc. (Nasdaq: EXEL) announced that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after market close. Following the release, Exelixis management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Details for accessing the conference call and webcast replay are available on the company's website.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

https://finance.yahoo.com/healthcare/articles/exelixis-release-third-quarter-2026-200500156.html
Exelixis, Inc. (Nasdaq: EXEL) announced it will release its third-quarter 2026 financial results on Thursday, October 29, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Access to the event will be available through the company's website and via registration for the conference call.
Advertisement

Exelixis, Inc. (EXEL) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/EXEL/
This article provides a comprehensive overview of Exelixis, Inc. (EXEL), including its current stock price, financial statistics, and company profile. It details the company's oncology-focused operations, key pharmaceutical products like CABOMETYX and COMETRIQ, and its development pipeline. The article also covers performance metrics, earnings trends, analyst insights, and financial highlights for potential investors.

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com

https://ca.investing.com/news/stock-market-news/exelixis-inc-stock-hits-alltime-high-at-6121-usd-93CH-4876495
Exelixis Inc. (EXEL) stock reached an all-time high of $61.23, demonstrating a significant 57.99% increase over the past year and a market capitalization of $15.08 billion. Despite this strong performance, InvestingPro analysis suggests the stock is overvalued relative to its Fair Value, even though the company maintains an "EXCELLENT" financial health score. Recent news includes beating Q2 2026 earnings expectations but a slight revenue miss, a downward revision of full-year revenue guidance due to slower NET business growth, and an FDA extension for zanzalintinib's review period.

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

https://www.morningstar.com/news/pr-newswire/20261012ny70326/kuehn-law-encourages-investors-of-exelixis-inc-to-contact-law-firm
Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) concerning self-dealing. Long-term EXEL shareholders are encouraged to contact the firm for a free consultation, as they may be entitled to damages and corporate governance reforms. The firm emphasizes that shareholder participation is crucial for maintaining the integrity and fairness of financial markets.

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

https://www.tradingview.com/news/prnewswire:0263d50708aaf:0-kuehn-law-encourages-investors-of-exelixis-inc-to-contact-law-firm/
Kuehn Law is encouraging investors of EXELIXIS, Inc. (EXEL) to contact their law firm. The news item from PR Newswire indicates that EXELIXIS investors might have a legal inquiry or concern that Kuehn Law is addressing.

Exelixis Inc stock hits all-time high at 61.21 USD

https://www.investing.com/news/company-news/exelixis-inc-stock-hits-alltime-high-at-6121-usd-93CH-4944721
Exelixis Inc. (EXEL) stock reached an all-time high of $61.23, now boasting a market capitalization of $15.08 billion and a 57.99% increase over the past year. Despite this, InvestingPro analysis suggests the stock is overvalued, though the company maintains an "EXCELLENT" financial health score. Recent news includes beating EPS expectations in Q2 2026 but slightly missing revenue, a downward revision of full-year revenue guidance, and an FDA review extension for its zanzalintinib drug.
Advertisement

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com

https://in.investing.com/news/stock-market-news/exelixis-inc-stock-hits-alltime-high-at-6121-usd-93CH-5628924
Exelixis Inc (EXEL) stock reached an all-time high of $61.23, reflecting a 57.99% increase over the past year and bringing its market capitalization to $15.08 billion. Despite this strong performance, InvestingPro analysis indicates the stock may be overvalued relative to its Fair Value, though the company maintains an "EXCELLENT" financial health score. Recent news includes beating Q2 2026 EPS expectations but missing revenue targets, a downward revision of full-year revenue guidance, and an FDA review extension for zanzalintinib, alongside varied analyst ratings.

Price-Driven Insight from (EXEL) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/90/Price-Driven_Insight_from_EXEL_for_Rule-Based_Strategy_101126054402_1791755042.html
This article provides a price-driven analysis for Exelixis Inc. (NASDAQ: EXEL), highlighting strong near-term sentiment, a mid-channel oscillation pattern, and an exceptional short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various holding periods.

Exelixis Price Target Raised to $51.00/Share From $45.00 by RBC Capital

https://www.moomoo.com/news/post/1000848637/exelixis-price-target-raised-to-51-00-share-from-45
RBC Capital has increased its price target for Exelixis (EXEL) shares from $45.00 to $51.00. This updated price target suggests a potential upside from the stock's previous closing price of $23.18. The rating on Exelixis remains "Outperform" by RBC Capital.

Bank of America Securities Sticks to Its Sell Rating for Exelixis (EXEL)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/5684661/bank-of-america-securities-sticks-to-its-sell-rating-for-exelixis-exel/
Bank of America Securities has reiterated its Sell rating for Exelixis (EXEL), setting a price target of $41.00. Analyst Jason Gerberry's rating comes despite the company reporting increased quarterly revenue and net profit. The consensus among analysts for Exelixis is currently a Hold with an average price target of $52.30.

EXEL Maintained by RBC Capital -- Price Target Raised to $51.00

https://www.gurufocus.com/news/9117418/exel-maintained-by-rbc-capital-price-target-raised-to-5100
RBC Capital has maintained its 'Sector Perform' rating for Exelixis (EXEL) while raising its price target to $51.00, indicating a positive outlook despite the stock being considered overvalued by GuruFocus' GF Value™. Exelixis, a biopharmaceutical company specializing in cancer therapies, has a strong GF Score™ of 92/100 due to its excellent growth and profitability, but its valuation rank is lower. Insider activity shows a mixed sentiment with recent sales, suggesting caution despite analyst confidence in the company's future potential.
Advertisement

RBC Capital maintains Sector Perform rating on Exelixis, $51 price target

https://www.tradingview.com/news/tradingview:48cc8de0aed6e:0-rbc-capital-maintains-sector-perform-rating-on-exelixis-51-price-target/
RBC Capital has reaffirmed its Sector Perform rating for Exelixis (EXEL) with a $51 price target, indicating a 13.6% potential downside from its previous close. The rating reflects the strong market position of Exelixis's lead product, Cabozantinib, in kidney and liver cancer treatments, which provides a stable revenue base despite an impending patent cliff in 2030. However, developmental risks associated with its promising next-generation drug zanzalintinib, which needs to outperform Cabozantinib, contribute to the balanced risk and reward outlook.

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating

https://www.marketscreener.com/news/rbc-raises-price-target-on-exelixis-to-51-from-45-keeps-sector-perform-rating-ce785ddfd081fe25
RBC Capital Markets has increased its price target for Exelixis (EXEL) shares to $51 from $45, while maintaining a "Sector Perform" rating on the stock. This adjustment comes as RBC anticipates successful clinical trials for Exelixis's Zanzalintinib cancer treatment.

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says

https://www.marketscreener.com/news/exelixis-zanzalintinib-clinical-trials-for-cancer-highly-likely-to-succeed-rbc-says-ce785ddcd88cf022
RBC believes that Exelixis' clinical trials for Zanzalintinib, a cancer treatment, are highly likely to succeed. This positive outlook follows RBC's recent adjustment of Exelixis' price target from $45 to $51, while maintaining a Sector Perform rating. The article also notes recent FDA activity regarding Zanzalintinib, including an extended review period for its New Drug Application in combination with Atezolizumab for metastatic colorectal cancer.

EXEL Stock Fundamentals & Key Ratios

https://pluang.com/en/asset/usstock/EXEL/11376/fundamentals
This article provides fundamental data and key ratios for Exelixis Inc. Common Stock (EXEL). It includes market capitalization, trading volume, sector, 52-week high and low prices, typical hold time, and enterprise value. The information is presented by Pluang, an investment platform, encouraging users to track and trade EXEL shares with real-time market data.

Exelixis Is Maintained at Sector Perform by RBC Capital

https://www.moomoo.com/news/post/1000774643/exelixis-is-maintained-at-sector-perform-by-rbc-capital
RBC Capital has reiterated its "Sector Perform" rating for Exelixis, a pharmaceutical company. The article maintains the existing rating without specifying any changes to the price target or providing detailed reasons for the reaffirmation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement